bronchiol
common
caus
hospit
infant
less
month
age
diseas
caus
approxim
annual
hospit
unit
state
ralston
et
al
friedman
et
al
hasegawa
et
al
signific
amount
literatur
subject
publish
sinc
first
iter
american
academi
pediatr
aap
clinic
practic
guidelin
american
academi
pediatr
subcommitte
diagnosi
manag
bronchiol
aap
canadian
paediatr
societi
cp
publish
updat
recommend
diagnosi
manag
prevent
bronchiol
novemb
ralston
et
al
friedman
et
al
reflect
literatur
surround
manag
challeng
entiti
new
guidelin
contain
major
action
statement
recommend
use
test
therapi
tabl
summar
major
updat
aap
iter
viral
lower
respiratori
tract
pathogen
caus
bronchiol
infant
children
less
year
old
disord
selflimit
character
edema
acut
inflamm
necrosi
epitheli
cell
line
small
airway
combin
increas
mucou
product
clinic
patient
manifest
typic
includ
cough
rhiniti
start
ill
often
progress
variabl
degre
respiratori
distress
accessori
muscl
use
tachypnea
wheez
rale
nasal
flare
andor
hypoxia
mild
manifest
symptom
often
manag
outpati
mani
still
requir
hospit
support
care
moder
sever
diseas
ralston
et
al
friedman
et
al
agenc
healthcar
research
qualiti
decis
admit
patient
base
clinic
judgment
assess
respiratori
statu
abil
maintain
hydrat
risk
sever
diseas
progress
famili
abil
care
patient
home
friedman
et
al
respiratori
syncyti
viru
rsv
common
etiolog
bronchiol
agenc
healthcar
research
qualiti
miller
et
al
mullin
et
al
virus
caus
clinic
manifest
includ
human
rhinoviru
influenza
coronaviru
human
metapneumoviru
parainfluenza
viru
miller
et
al
decemb
march
typic
time
highest
incid
rsv
region
variat
demonstr
high
rsv
preval
earli
august
late
may
mullin
et
al
center
diseas
control
prevent
also
virus
present
month
mean
bronchiol
seen
year
round
agenc
healthcar
research
qualiti
diagnosi
ofbronchiol
made
clinic
histori
physic
exam
provid
use
clinic
assess
distinguish
viral
bronchiol
disord
character
sever
ill
identifi
risk
factor
sever
diseas
guidelin
recommend
routin
use
chest
xray
viral
test
lab
test
studi
correl
diseas
sever
clinic
outcom
provid
valu
patient
may
lead
unnecessari
antibiot
hospit
ralston
et
al
friedman
et
al
mansbach
et
al
swingler
et
al
schuh
et
al
sever
studi
includ
mani
metaanalys
systemat
review
use
bronchodil
bronchiol
shown
lack
effect
need
hospit
diseas
resolut
length
stay
lo
effect
may
clinic
symptom
score
transient
ralston
et
al
friedman
et
al
kellner
et
al
flore
horwitz
zorc
hall
wainwright
gadomski
scribani
major
chang
treatment
recommend
aap
guidelin
also
includ
cp
guidelin
recommend
use
bronchodil
albuterol
salbutamol
bronchiol
even
trial
ralston
et
al
friedman
et
al
guidelin
also
recommend
use
nebul
epinephrin
hospit
patient
bronchiol
due
multipl
studi
review
show
lack
effect
lo
outcom
chang
respiratori
rate
respiratori
effort
time
oxygen
hartl
et
al
hartl
et
al
b
wainwright
et
al
skjerven
et
al
one
larg
multicent
studi
also
found
use
fix
schedul
prolong
lo
skjerven
et
al
use
epinephrin
emerg
depart
outpati
set
howev
remain
controversi
one
larg
multicent
random
doubleblind
placebocontrol
trial
infant
compar
hospit
rate
day
four
studi
group
nebul
epinephrin
plu
oral
dexamethason
nebul
epinephrin
plu
oral
placebo
nebul
placebo
plu
oral
dexamethason
nebul
placebo
plu
oral
placebo
plint
et
al
found
group
receiv
epinephrin
combin
dexamethason
less
like
hospit
day
doubl
placebo
group
howev
adjust
multipl
comparison
differ
longer
statist
signific
cochran
review
hartl
et
al
also
found
rate
hospit
admiss
reduc
day
first
emerg
depart
visit
overal
day
cp
guidelin
suggest
provid
may
trial
dose
nebul
epinephrin
care
monitor
clinic
respons
aap
guidelin
caution
use
sinc
home
use
routin
transient
effect
seen
observ
affect
overal
cours
ill
ralston
et
al
friedman
et
al
new
aap
manag
guidelin
also
includ
cp
guidelin
recommend
use
ofhyperton
salin
ht
ht
administ
patient
outpati
emerg
depart
set
effect
hospit
rate
ralston
et
al
friedman
et
al
zhang
et
al
guidelin
suggest
ht
may
use
hospit
patient
due
avail
literatur
show
reduct
length
stay
lo
zhang
et
al
badgett
et
al
publish
literatur
howev
inconsist
find
potenti
effect
reduct
lo
involv
patient
popul
averag
lo
day
averag
lo
us
day
ralston
et
al
friedman
et
al
brook
et
al
sinc
public
guidelin
newer
evid
suggest
origin
report
benefit
ht
may
overst
first
result
two
us
random
control
trial
fail
show
effect
ht
relat
length
stay
second
june
brook
et
al
publish
reanalysi
studi
includ
two
prior
metaanalys
among
rct
report
lo
outcom
found
two
main
sourc
excess
heterogen
first
outlier
studi
popul
significantli
differ
discharg
criteria
substanti
longer
expect
lo
second
found
baselin
differ
treatment
arm
day
ill
enrol
result
systemat
bia
favor
treatment
arm
small
posit
studi
present
later
ill
like
alloc
ht
group
author
control
factor
resolv
heterogen
ht
longer
effect
lo
nasal
suction
longbeen
common
therapeut
intervent
clear
increas
mucou
produc
bronchiol
temporarili
reduc
increas
work
breath
despit
obviou
reason
use
support
measur
littl
data
exist
role
suction
manag
patient
bronchiol
retrospect
cohort
studi
publish
mussman
et
al
assess
relationship
frequenc
type
suction
lo
author
hypothes
repeat
nasopharyng
suction
deep
suction
compar
noninvas
nasal
suction
would
lead
wors
outcom
due
local
trauma
frequent
noninvas
suction
would
improv
outcom
infant
month
age
includ
infant
devic
type
cohort
deep
vs
noninvas
suction
infant
suction
laps
cohort
exclud
patient
intub
tracheostomi
admit
picu
lo
less
h
includ
index
admiss
percentag
deep
suction
exposur
first
h
admiss
calcul
categor
four
rang
data
analyz
use
multivari
model
adjust
invers
weight
propens
receiv
deep
suction
suction
laps
group
number
sequenti
suction
event
separ
h
count
first
h
admiss
found
statist
signific
associ
increas
length
stay
group
deep
suction
first
h
laps
greater
h
mean
differ
day
day
respect
studi
need
studi
suggest
aggress
nasopharyng
deep
suction
may
prolong
lo
patient
benefit
frequent
less
aggress
nasal
suction
find
complement
prior
studi
predictor
lo
bronchiol
also
found
signific
associ
nasopharyng
suction
earli
hospit
increas
lo
weisgerb
et
al
infant
poor
feed
difficulti
feed
safe
due
level
respiratori
distress
may
receiv
either
nasogastr
ng
intraven
fluid
ralston
et
al
friedman
et
al
inclus
ng
fluid
new
aap
guidelin
recommend
hydrat
via
rout
appear
safe
older
young
infant
oakley
et
al
multicent
open
random
trial
oakley
et
al
compar
ng
iv
fluid
therapi
infant
month
age
bronchiol
found
signific
differ
length
stay
escal
care
need
ventil
support
advers
event
group
differ
parent
satisfact
score
group
ng
rout
higher
success
rate
insert
fewer
requir
attempt
insert
iv
rout
oakley
et
al
recent
descript
retrospect
cohort
studi
examin
use
ng
fluid
infant
month
age
bronchiol
found
differ
rate
advers
event
ng
iv
group
aspir
event
differ
lo
oakley
et
al
past
two
decad
hospit
rate
children
bronchiol
significantli
increas
mortal
rate
remain
constant
one
implic
contributor
rise
hospit
increas
use
pulseoximetri
time
schroeder
et
al
oxygen
satur
correl
proxi
respiratori
distress
wang
et
al
yet
shown
main
factor
decis
admit
lengthen
lo
ralston
et
al
schroeder
et
al
cunningham
mcmurray
physiolog
oxygen
satur
take
much
higher
elev
arteri
pressur
oxygen
caus
increas
satur
versu
satur
increas
satur
threshold
clear
clinic
benefit
ralston
et
al
anaesthesia
uk
also
studi
healthi
infant
show
transient
hypoxemia
occur
commonli
without
appar
harm
hunt
et
al
intermitt
hypoxemia
asthmat
children
experi
caus
intellectu
impair
behavior
problem
rivetveld
colland
bender
et
al
base
data
guidelin
give
recommend
provid
may
choos
use
oxygen
patient
oxyhemoglobin
satur
equal
higher
ralston
et
al
friedman
et
al
use
continu
pulseoximetri
infant
children
bronchiol
ralston
et
al
data
sinc
publish
support
recommend
cunningham
et
al
mcculloh
et
al
cunningham
et
al
perform
multicent
random
control
doubleblind
equival
studi
see
target
infant
bronchiol
equival
target
ill
resolut
accomplish
randomli
assign
one
group
infant
connect
modifi
oximet
would
display
measur
valu
anoth
group
infant
place
standard
oximet
display
accur
measur
valu
group
receiv
oxygen
display
valu
standard
practic
found
oxygen
satur
target
equal
safe
effect
target
differ
group
advers
event
escal
care
modifi
group
also
significantli
shorter
lo
time
oxygen
fewer
readmiss
increas
postdischarg
parent
anxieti
multicent
random
superior
trial
mcculloh
et
al
studi
effect
intermitt
versu
continu
pulseoximetri
use
lo
nonhypoxem
bronchiol
patient
found
similar
lo
group
intermitt
group
escal
care
requir
diagnost
therapeut
intervent
suggest
provid
routin
consid
use
intermitt
pulseoximetri
monitor
patient
bronchiol
clinic
improv
exposur
tobacco
smoke
increas
sever
ill
risk
hospit
provid
screen
everi
patient
bronchiol
tobacco
smoke
exposur
counsel
caregiv
risk
associ
provid
recommend
resourc
smoke
cessat
famili
provid
also
recommend
encourag
exclus
breastfeed
least
month
reduc
incid
sever
bronchiol
share
decisionmak
provid
caregiv
happen
provid
educ
evidencebas
diagnosi
treatment
prevent
expect
cours
ill
ralston
et
al
urinari
tract
infect
uti
common
seriou
bacteri
infect
sbi
young
children
robert
et
al
roman
et
al
diagnosi
treatment
infant
young
children
febril
uti
seen
major
chang
past
year
aap
publish
updat
clinic
practic
guidelin
diagnosi
manag
initi
febril
uti
month
age
robert
et
al
one
import
chang
includ
requir
evid
infect
urinalysi
pyuria
andor
bacteriuria
presenc
least
colonyform
unit
cfu
per
ml
urin
cultur
specimen
obtain
catheter
suprapub
aspir
posit
diagnos
uti
guidelin
recommend
routin
use
void
cystourethrogram
vcug
initi
febril
uti
advis
instead
screen
renal
bladder
ultrasound
rbu
vcug
advis
rbu
show
hydronephrosi
scar
sign
highgrad
vesicoureter
reflux
obstruct
uropathi
recurr
febril
uti
robert
et
al
updat
guidelin
includ
requir
evid
pyuria
ua
diagnos
uti
distinguish
true
uti
asymptomat
bacteriuria
sinc
presenc
pyuria
indic
presenc
inflammatori
respons
true
infect
robert
et
al
robert
howev
concern
sensit
ua
young
infant
continu
sinc
guidelin
includ
infant
month
age
sinc
sensit
ua
children
report
schroeder
et
al
question
howev
whether
neg
ua
posit
urin
cultur
repres
falseneg
ua
falseposit
urin
cultur
asymptomat
bacteriuria
febril
infant
assess
diagnost
accuraci
ua
gener
healthi
febril
infant
month
age
schroeder
et
al
use
popul
infant
bacterem
uti
defin
organ
urin
blood
cfu
per
ml
urin
cultur
multicent
databas
repres
true
infect
infant
calcul
ua
specif
use
sampl
febril
infant
month
age
neg
urin
cultur
workup
seriou
bacteri
infect
infant
leukocyt
esteras
sensit
ci
specif
ci
pyuria
white
blood
cellshighpow
field
sensit
ci
specif
ci
result
differ
significantli
infant
day
old
infant
day
old
studi
highlight
ua
highli
sensit
test
diagnos
uti
author
acknowledg
result
could
due
spectrum
bia
discuss
literatur
support
lack
differ
nonbacterem
bacterem
uti
discuss
roman
et
al
schroeder
et
al
discrep
result
show
high
sensit
ua
prior
lower
sensit
report
like
due
urin
cultur
faulti
gold
standard
use
prior
studi
mani
posit
urin
cultur
repres
asymptomat
bacteriuria
schroeder
et
al
robert
whether
give
prophylact
antibiot
infant
young
children
vesicoureter
reflux
vur
remain
sourc
debat
result
random
intervent
children
vesicoureter
reflux
rivur
trial
hoberman
et
al
show
prophylact
antibiot
trimethoprimsulfamethoxazol
reduc
risk
recurr
uti
children
vur
particularli
effect
whose
initi
uti
febril
baselin
bowel
bladder
dysfunct
compar
effect
base
sever
vur
though
prophylaxi
effect
grade
reflux
vs
higher
risk
grade
also
find
differ
occurr
renal
scar
studi
placebo
group
studi
group
time
higher
rate
resist
organ
caus
recurr
infect
hoberman
et
al
question
effect
prophylact
antibiot
occurr
renal
scar
could
truli
answer
studi
given
underpow
detect
outcom
rivur
trial
show
effect
prophylact
antibiot
prevent
recurr
uti
children
vur
other
question
effici
manag
approach
afshar
carafuent
et
al
base
number
need
treat
one
would
treat
eight
children
year
prophylact
antibiot
prevent
one
uti
afshar
other
highlight
fact
take
year
see
signific
differ
rate
uti
differ
seen
patient
younger
year
old
grade
vur
vs
grade
resolut
vur
seen
mani
patient
may
contribut
effect
carafuent
et
al
decis
whether
use
prophylact
antibiot
continu
multifactori
provid
consid
factor
morbid
relat
uti
cost
side
effect
potenti
resist
organ
number
need
treat
likelihood
complianc
parent
prefer
share
decisionmak
also
worth
highlight
natur
histori
vur
selfresolut
almost
wors
case
robert
et
al
look
instead
subgroup
patient
may
like
benefit
bowel
bladder
dysfunct
may
wiser
choic
ongo
debat
uti
prophylaxi
afshar
signific
amount
evid
support
conclus
oral
parenter
antibiot
equal
efficaci
infant
young
children
febril
uti
robert
et
al
hoberman
et
al
strohmeier
et
al
patient
routin
requir
hospit
parenter
antibiot
unless
patient
illappear
toler
oral
intak
well
enough
maintain
hydrat
robert
et
al
manag
patient
bacterem
uti
organ
urin
blood
obtain
blood
cultur
patient
uti
pose
challeng
current
guidelin
address
howev
current
evid
demonstr
despit
variabl
manag
littl
differ
clinic
outcom
roman
et
al
schroeder
et
al
multipl
studi
demonstr
bacterem
uti
occur
infrequ
preval
decreas
increas
age
patient
without
bacteremia
lack
easili
identifi
clinic
differ
hoberman
et
al
honkinen
et
al
schnadow
et
al
newman
et
al
roman
et
al
publish
retrospect
crosssect
doubl
cohort
studi
larg
institut
confirm
find
addit
studi
demonstr
declin
number
blood
cultur
obtain
infant
uti
studi
period
differ
treatment
cours
yet
equal
outcom
infant
year
age
uti
without
bacteremia
despit
consider
variat
manag
bacterem
infant
parenter
antibiot
rang
day
clinic
outcom
excel
infant
recurr
uti
within
day
requir
icu
transfer
escal
care
posit
csf
cultur
test
posit
repeat
blood
cultur
roman
et
al
despit
find
studi
literatur
found
detect
bacteremia
lead
longer
hospit
parenter
therapi
honkinen
et
al
magin
et
al
averbuch
bradi
et
al
expand
schroeder
et
al
conduct
multicent
retrospect
cohort
studi
assess
predictor
parenter
antibiot
durat
associ
treatment
durat
relaps
within
day
infant
month
age
bacterem
uti
includ
infant
bacterem
uti
hospit
healthcar
institut
across
unit
state
exclud
major
comorbid
indwel
urinari
central
venou
cathet
time
cultur
initi
manag
icu
found
signific
variabl
durat
parenter
antibiot
preval
day
without
impact
outcom
none
relaps
bacterem
uti
none
deterior
treatment
six
relaps
nonbacterem
uti
organ
ci
associ
abnorm
vcug
differ
durat
parenter
antibiot
without
relaps
nonbacterem
uti
institut
practic
account
variabl
durat
found
five
independ
predictor
durat
partial
account
variabl
older
age
femal
gender
year
blood
cultur
associ
slightli
shorter
cours
posit
repeat
blood
cultur
acut
treatment
none
coli
organ
lengthen
treatment
although
infant
latter
factor
rather
clinic
respons
therapi
guid
durat
parenter
antibiot
tendenc
toward
certain
number
day
day
suggest
provid
instead
pick
fix
number
treatment
day
schroeder
et
al
larg
retrospect
studi
provid
largest
set
data
demonstr
bacterem
uti
may
differ
nonbacterem
uti
question
need
blood
cultur
infant
uti
show
lack
appar
benefit
prolong
hospit
parenter
antibiot
infant
bacterem
uti
recov
clinic
especi
face
obviou
risk
hospit
roman
et
al
schroeder
et
al
fever
without
local
sourc
young
infant
continu
common
problem
present
clinic
dilemma
chang
epidemiolog
seriou
bacteri
infect
sbi
age
group
larg
understudi
chang
choic
empir
antibiot
therapi
biondi
et
al
mischler
et
al
vaccin
develop
larg
reduc
incid
bacteremia
mening
also
chang
epidemiolog
past
two
decad
larg
result
chang
screen
treatment
group
b
streptococcu
gb
prior
deliveri
rigor
food
safeti
guidelin
mischler
et
al
mani
studi
character
epidemiolog
bacteremia
era
limit
small
sampl
size
geograph
isol
biondi
et
al
mischler
et
al
biondi
et
al
publish
first
larg
geograph
divers
studi
identifi
caus
bacteremia
otherwis
healthi
febril
infant
day
old
outsid
intens
care
unit
icu
perform
retrospect
review
posit
blood
cultur
patient
popul
admit
gener
inpati
unit
across
six
hospit
system
across
unit
state
found
patient
pathogen
blood
cultur
e
coli
preval
organ
gb
second
preval
found
listeria
monocytogen
biondi
et
al
similarli
followup
studi
publish
mischler
et
al
larger
nation
repres
sampl
sampl
site
across
countri
demonstr
e
coli
preval
follow
gb
case
listeria
monocytogen
studi
also
discuss
rate
concurr
uti
mening
pathogen
contribut
discuss
chang
type
caus
sbi
young
infant
biondi
et
al
mischler
et
al
studi
demonstr
current
empir
antibiot
strategi
treat
young
infant
risk
sbi
may
outdat
epidemiolog
bacteri
pathogen
chang
time
anoth
chang
trend
inpati
evalu
otherwis
healthi
febril
infant
day
age
length
observ
period
standard
observ
infant
h
set
time
blood
cultur
manual
assess
infrequ
interv
biondi
et
al
laboratori
use
continu
autom
monitor
system
time
detect
bacteri
growth
significantli
shorter
larg
multicent
retrospect
studi
pathogen
blood
cultur
patient
popul
turn
posit
h
respect
biondi
et
al
find
combin
overal
low
rate
bacteremia
age
group
suggest
h
observ
period
adequ
detect
clinic
signific
bacteremia
impact
noteworthi
given
possibl
signific
decreas
length
stay
common
reason
hospit
infant
safe
reduc
observ
time
mani
infant
patient
popul
reduc
risk
cost
complic
associ
hospit
biondi
et
al
appar
lifethreaten
event
alt
defin
episod
frighten
observ
character
combin
apnea
central
occasion
obstruct
color
chang
usual
cyanot
pallid
occasion
erythemat
plethor
mark
chang
muscl
tone
usual
mark
limp
choke
gag
case
observ
fear
infant
die
nation
institut
health
definit
come
consensu
develop
confer
held
nation
institut
health
purpos
address
relationship
sudden
infant
death
syndrom
sid
apnea
safeti
effect
home
monitor
nation
institut
health
young
patient
often
hospit
observ
alt
larg
uncertainti
provid
parent
feel
know
patient
risk
repeat
event
seriou
underli
condit
precipit
event
much
uncertainti
come
lack
specif
definit
alt
lack
consensu
manag
wellappear
patient
unexplain
alt
tieder
et
al
may
american
academi
pediatr
publish
first
clinic
practic
guidelin
evalu
infant
appar
life
threaten
event
tieder
et
al
guidelin
achiev
three
primari
object
give
recommend
replac
term
appar
life
threaten
event
alt
specificallydefin
brief
resolv
unexplain
event
brue
stratifi
infant
low
high
risk
base
likelihood
seriou
underli
condit
provid
evidencebas
manag
recommend
lowerrisk
infant
provid
recommend
evalu
manag
lowerrisk
infant
guidelin
intend
reduc
unnecessari
costli
intervent
promot
patient
familycent
care
improv
patient
outcom
also
provid
support
implement
identifi
area
need
research
guidelin
avoid
provid
recommend
higherrisk
infant
insuffici
evid
clinic
practic
guidelin
avail
specif
condit
high
risk
infant
may
tieder
et
al
brue
defin
event
occur
infant
less
year
age
observ
describ
sudden
brief
resolv
includ
follow
cyanosi
pallor
absent
decreas
irregular
breath
mark
chang
tone
mean
hyper
hypotonia
alter
level
respons
see
tabl
full
list
inclus
exclus
criteria
term
brue
use
diagnosi
explan
event
obtain
appropri
histori
physic
exam
instanc
fever
nasal
congest
increas
work
breath
present
event
may
explain
temporari
airway
obstruct
viral
infect
altern
event
choke
feed
spit
may
indic
gastroesophag
reflux
ger
anoth
gastrointestin
caus
brue
definit
provid
specif
origin
alt
definit
lack
allow
applic
clinic
care
research
specif
criteria
provid
focu
infant
unexplain
reason
event
clearli
assess
risk
well
remov
featur
consist
normal
infant
physiolog
selflimit
condit
also
diagnosi
base
object
character
featur
clinician
make
rather
caregiv
percept
event
lifethreaten
prior
definit
suggest
precis
diagnosi
made
thorough
histori
physic
may
prevent
unnecessari
test
hospit
remov
uncertainti
perceiv
risk
recurr
event
compel
test
observ
first
place
guidelin
provid
extens
list
histor
physic
exam
featur
provid
consid
evalu
potenti
brue
tieder
et
al
base
extens
review
alt
literatur
new
brue
guidelin
identifi
subset
patient
unlik
recurr
event
undiagnos
seriou
condit
patient
lower
risk
advers
outcom
like
manag
safe
without
extens
diagnost
evalu
hospit
tieder
et
al
follow
criteria
encompass
lower
risk
age
daysgest
age
week
postconcept
age
weeksfirst
brue
ever
occur
clustersdur
event
minno
cpr
requir
train
medic
providerno
concern
histor
featur
see
tabl
guidelin
concern
physic
exam
find
see
tabl
guidelin
identifi
patient
brue
fall
lower
risk
categori
provid
follow
key
action
statement
regard
recommend
manag
categor
base
strength
recommend
tieder
et
al
provid
educ
caregiv
brue
engag
shareddecisionmak
guid
evalu
disposit
followupoff
resourc
cpr
train
caregiv
provid
may
obtain
pertussi
test
ecgbriefli
monitor
patient
continu
pulseox
serial
observ
provid
obtain
wbc
count
blood
cultur
csf
analysi
cultur
serum
sodium
potassium
chlorid
blood
urea
nitrogen
creatinin
calcium
ammonia
blood
gase
urin
organ
acid
plasma
amino
acid
acylcarnitin
chest
radiograph
echocardiogram
eeg
studi
ger
lab
evalu
anemiainiti
home
cardiorespiratori
monitoringprescrib
acid
suppress
therapi
antiepilept
medic
provid
need
obtain
viral
respiratori
test
urinalysi
blood
glucos
serum
bicarbon
serum
lactic
acid
neuroimagingadmit
patient
hospit
sole
cardiorespiratori
monitor
new
guidelin
limit
scope
offer
initi
pathway
standard
manag
common
inpati
entiti
guidelin
howev
signific
limit
import
author
decid
limit
recommend
children
month
age
signific
number
children
present
hospit
brue
less
month
thu
guidelin
may
appli
signific
number
patient
standard
need
futur
research
address
manag
diagnosi
younger
infant
month
age
current
fall
high
risk
group
osteomyelitisi
bacteri
infect
account
pediatr
hospit
gener
requir
hospit
initi
diagnosi
manag
often
involv
prolong
cours
antibiot
prevent
chronic
infect
complic
zaouti
et
al
resolut
acut
symptom
fever
pain
disabl
children
complet
week
antibiot
therapi
home
recent
recommend
rout
administr
central
venou
cathet
usual
peripher
insert
central
cathet
picc
keren
et
al
howev
publish
case
seri
demonstr
excel
outcom
patient
treat
short
cours
parenter
antibiot
transit
earli
oral
antibiot
complet
therapi
peltola
et
al
le
saux
et
al
jagodzinski
et
al
kolyva
et
al
arnold
et
al
benefit
earli
transit
oral
antibiot
therapi
includ
lower
cost
complic
picc
effect
deliv
antibiot
often
associ
high
rate
infecti
thrombot
mechan
complic
ruebner
et
al
bourgeoi
et
al
larg
prospect
random
control
trial
rct
compar
oral
intraven
iv
rout
antibiot
therapi
two
larg
retrospect
cohort
studi
compar
earli
transit
oral
versu
iv
antibiot
children
osteomyel
zaouti
et
al
keren
et
al
second
studi
design
way
mimic
rct
keren
et
al
studi
use
data
pediatr
health
inform
system
phi
databas
contain
administr
bill
data
freestand
children
hospit
associ
children
hospit
associ
data
system
includ
inform
demograph
diagnosi
medic
procedur
repeat
hospit
zaouti
et
al
zaouti
et
al
publish
first
larg
studi
look
degre
variat
across
hospit
use
earli
transit
oral
antibiot
whether
associ
therapi
treatment
failur
primari
outcom
treatment
failur
defin
rehospit
within
month
due
acut
chronic
osteomyel
potenti
complic
acut
osteomyel
musculoskelet
surgic
procedur
secondari
outcom
rehospit
within
month
due
catheterrel
complic
antibioticrel
advers
drug
reaction
reason
author
obtain
data
children
month
year
acut
osteomyel
meet
inclus
criteria
freestand
children
hospit
central
venou
cathet
cvc
prolong
iv
antibiot
transit
oral
antibiot
prior
discharg
signific
differ
group
term
demograph
site
infect
lo
surgic
intervent
infect
organ
diseas
sever
inhospit
antibiot
therapi
found
differ
treatment
failur
group
iv
group
oral
group
author
also
demonstr
signific
variat
across
hospit
proport
children
cvc
prolong
antibiot
rang
data
secondari
outcom
show
children
prolong
iv
therapi
group
like
treatmentrel
complic
eg
cathet
relat
complic
antibiot
relat
complic
significantli
higher
readmiss
rate
antimicrobi
complic
significantli
higher
overal
rehospit
rate
reason
author
conclud
two
method
treatment
equal
effect
earli
transit
oral
therapi
associ
fewer
complic
result
studi
encourag
hospit
develop
clinic
practic
guidelin
protocol
earli
transit
oral
antibiot
thu
reduc
practic
variat
zaouti
et
al
promis
studi
signific
limit
may
partli
contribut
lack
widespread
reduct
picc
use
favor
oral
treatment
rout
among
hospit
limit
includ
retrospect
natur
lack
valid
osteomyel
diagnosi
treatment
choic
adjust
sever
ill
inform
reason
readmiss
revisit
keren
et
al
publish
subsequ
studi
seek
compar
effect
complic
rate
two
treatment
modal
earli
transit
oral
antibiot
vs
prolong
iv
antibiot
address
zaouti
et
al
limit
treatment
failur
primari
outcom
defin
revisit
ed
rehospit
chang
antibiot
length
treatment
switch
oral
picc
rout
patholog
bone
fractur
surgic
procedur
relat
infect
ie
abscess
drainag
debrid
bone
biopsi
etc
secondari
outcom
includ
return
ed
visit
rehospit
antibiot
piccrel
complic
composit
treatment
failur
studi
also
util
administr
data
phi
databas
supplement
addit
clinic
inform
detail
manual
chart
review
thu
valid
treatment
alloc
outcom
covari
studi
also
use
within
acrosshospit
full
match
base
propens
score
account
confound
hospit
patient
level
still
robust
avoid
confound
random
trial
propens
base
match
mimic
rct
close
compar
similar
patient
arm
studi
addit
studi
improv
prior
studi
includ
children
hospit
methicillinresist
aureu
mrsa
preval
keren
et
al
result
nearli
ident
zaouti
et
al
children
oral
antibiot
group
children
picc
antibiot
group
across
hospit
treatment
failur
rate
similar
oral
group
picc
group
includ
match
analys
stratifi
analys
find
risk
treatment
failur
increas
children
older
year
picc
group
howev
mrsa
caus
organ
impact
outcom
treatment
failur
base
treatment
rout
secondari
outcom
picc
group
piccrel
complic
picc
group
significantli
higher
risk
need
return
ed
visit
hospit
advers
event
match
analysi
acrosshospit
variat
use
picc
rout
give
antibiot
discharg
broad
rang
author
conclud
discharg
otherwis
healthi
patient
osteomyel
complet
antibiot
therapi
via
invas
picc
offer
advantag
less
invas
oral
antibiot
option
latter
confer
fewer
risk
complic
keren
et
al
studi
well
previous
publish
case
seri
demonstr
safeti
efficaci
transit
parenter
oral
antibiot
therapi
treatment
acut
osteomyel
other
studi
best
way
determin
time
transit
one
studi
arnold
et
al
author
conduct
singlecent
retrospect
studi
standard
practic
transit
parenter
antibiot
oral
antibiot
patient
clinic
improv
creactiv
protein
crp
level
mgdl
patient
review
one
treatment
failur
due
retain
infect
bone
fragment
joint
space
studi
includ
patient
cultureposit
infect
includ
mrsa
infect
arnold
et
al
anoth
singlecent
studi
chou
arjanda
evalu
patient
author
institut
transit
parenter
antibiot
oral
antibiot
crp
level
declin
per
protocol
includ
cultureposit
cultureneg
infect
found
use
declin
crp
level
day
period
combin
clinic
improv
safe
way
determin
time
transit
therapi
chou
arjanda
use
clinic
improv
combin
declin
crp
level
whether
near
normal
level
mgdl
use
way
determin
safe
transit
parenter
oral
antibiot
therapi
may
help
shorten
length
stay
standard
practic
pediatr
hospitalist
forefront
high
valu
care
pediatr
reflect
public
field
last
year
issu
receiv
much
attent
adult
medicin
public
pediatr
address
issu
particularli
issu
overus
pediatr
receiv
page
journal
overus
defin
provis
health
care
risk
harm
exce
potenti
benefit
benefit
neglig
fulli
inform
patient
would
forego
care
includ
overtreat
overdiagnosi
morgan
et
al
recent
public
pediatr
led
pediatr
hospitalist
review
year
worth
public
deal
issu
overus
pediatr
coon
et
al
american
board
intern
medicin
foundat
abimf
develop
choos
campaign
wwwchoosingwiselyorg
campaign
abimf
encourag
medic
societi
develop
list
five
item
within
scope
practic
thing
provid
patient
question
societi
hospit
medicin
publish
first
pediatr
list
methodolog
evid
support
list
also
later
publish
journal
hospit
medicin
quinonez
et
al
list
heavili
focus
respiratori
ill
particularli
bronchiol
unexpect
given
frequenc
diagnosi
inpati
set
investig
encourag
hospit
medicin
practition
util
list
guid
priorit
qualiti
improv
project
inde
recommend
limit
puls
oximetri
led
least
one
project
schondelmey
et
al
recommend
later
incorpor
aap
bronchiol
guidelin
ralston
et
al
tabl
author
involv
choos
wise
campaign
publish
comprehens
review
overdiagnosi
pediatr
coon
et
al
overdiagnosi
frequent
observ
adult
care
first
kind
review
explor
condit
pediatr
may
suffer
overdiagnosi
tabl
show
list
condit
review
author
condit
rang
adhd
bacteremia
sinc
public
review
evid
given
support
possibl
overdiagnosi
one
clear
exampl
overdiagnosi
hypoxemia
bronchiol
sinc
widespread
use
portabl
puls
oximet
seen
concomit
increas
admiss
bronchiol
hasegawa
et
al
sever
studi
demonstr
puls
oximetri
read
strong
influenc
clinician
decis
admit
patient
hospit
mower
et
al
convincingli
recent
canadian
random
control
trial
show
differ
point
within
normal
rang
oxygen
satur
influenc
decis
admit
patient
hospit
signific
way
despit
clinic
differ
schuh
et
al
group
also
demonstr
signific
desatur
even
occur
patient
manag
outpati
set
frequent
littl
associ
proxim
outcom
revisit
care
principi
et
al
